Clinical Trials Directory

Trials / Completed

CompletedNCT03070496

Multicenter Cohort of STEMI Patients

CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
281 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Ischemic heart disease is the leading cause of mortality with 7.2 million of death in industrialized countries (WHO data). Myocardial infarction corresponding to acute occlusion of a coronary artery is the most brutal form and the more severe ischemic myocardial disease. Every year in France, about 60,000 Myocardial infarctions hospitalized, 30,000 are diagnosed remotely and 30,000 are revealed by an inaugural sudden death. Although mortality from myocardial decreased by 30% over the past decade, the prognosis is pejorative and difficult to assess precisely. The management of the patient depends on these factors, and justifies an active search on these topics, including the mechanisms of the deleterious ventricular remodeling, myocardial inflammation, reperfusion injury which determines in particular the evolution to heart failure. Cohorts of patients with myocardial infarction are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool. The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after acute myocardial infarction. Secondary objectives of the HIBISCUS-STEMI cohort to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas: * Descriptive epidemiology of myocardial infarction and myocardial reperfusion * Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs * Assessment of the long-term effect of the treatment on the occurrence of heart failure and sudden death * Quality of life and personal consequences, family, professional and social myocardial infarction * Research of new diagnostic and prognostic biomarkers * Research projects (e.g. risk of developing kidney failure or stroke in patients with myocardial infarction compared to the general population).

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood samplingBlood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
PROCEDUREECGECG will be performed at 6 months after myocardial infarction
DEVICEMRIMRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
OTHERQuality of life questionnairePatients will pass a quality of life questionnaire at 12 months after myocardial infarction

Timeline

Start date
2017-03-07
Primary completion
2023-06-05
Completion
2023-06-05
First posted
2017-03-03
Last updated
2025-09-10

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03070496. Inclusion in this directory is not an endorsement.